Tumor-Infiltrating Lymphocytes (TILs) Are Dysfunctional
Many cancer patients mount a spontaneous antitumor T-cell response. However, evidence that the tumor microenvironment is immunosuppressive is accumulating. Tumor-infiltrating lymphocytes (TILs) freshly isolated from a variety of human tumor samples have often proven defective in lysing relevant target cells and secreting interferon-γ (IFNγ). TILs usually express immune checkpoint receptors, such as cytotoxic T lymphocyte associated protein 4 (CTLA4) and programmed cell death-1 (PDCD1, better known as PD-1), molecular features of exhausted lymphocytes. Blocking these receptors with antibodies has been shown to prolong survival of T cells and boost their proliferation upon activation in vitro. Such antibodies have shown their efficacy in a trial with advanced melanoma patients. 
Galectin Antagonists Boost Human TIL Functions
Galectins are lectins and thus recognize sugar moieties. By oligomerizing and crosslinking glycoproteins at the surface of T cells, galectins form glycoprotein-galectin lattices that impede the motility of receptors important for T-cell functions. We proposed several years ago that extracellular galectin-3 is responsible for deficiencies in TIL functions. 2, 3 Galectin-3 is secreted by cancer cells, macrophages, and activated T cells, and can accumulate in the tumor microenvironment. Treating CD8 + or CD4 + TILs freshly isolated from solid tumors or carcinoma ascites with galectin antagonists or with an anti-galectin-3 antibody, even for just a few hours, markedly increased their IFNγ secretion and cytotoxicity. 2, 3 Galectin-1 and galectin-3 recognize N-acetyl-lactosamine (LacNAc) motifs. Detaching galectin-1 and galectin-3 from cells can be achieved with competing sugars such as lactose, LacNAc, some dithiodigalactosides designed by Ulf Nilsson (Lund University) and developed by Galecto Biotech, or clinical-grade citrus pectin named GCS-100 developed by La Jolla Pharmaceuticals (Fig. 1) . Antibody B2C10 that is directed against the N-terminal part of galectin-3, at the opposite site of the carbohydrate recognition domain, can also detach galectin-3 from cells, most probably by disassembling galectin-3 oligomers, thus keeping it in a lower affinity form. We recently described that another clinical-grade product developed by Galectin Therapeutics, GM-CT-01, is also able to boost human TIL functions via disorganizing glycoproteingalectin lattices, without actually detaching galectins from cells. 4 GM-CT-01 is a galactomannan of about 50 kDa obtained by hydrolysis of guar gum, extracted from guar beans. Its half-life in Cynomolgus monkeys is between 12 to 18 h. GM-CT-01 interacts with a site in galectin-1, also present in galectin-3, opposite to the carbohydrate-binding domain, acting as an allosteric antagonist. 
Is TIL Immunosuppression a Story About Sugars and Galectins?
We have reported that freshly isolated CD8 + TILs that are heavily covered by galectin-3 are the CD8 + TILs that harbor a glycome rich in lactosamine motifs and thus strongly stained with Lycopersicon esculentum lectin (LEL). 4 These TILs were totally blocked for IFNγ secretion upon stimulation. Addition of galectin antagonists disorganizes galectin-glycoprotein lattices and retrieves the ability of the LEL high galectin-3 high CD8 + TILs to secrete IFNγ after stimulation. This is in agreement with our working hypothesis: a high percentage of TILs are activated lymphocytes, which therefore harbor many LacNAc motifs, the natural ligands of galectin-1 and -3. 5 The abundance of LacNAc motifs and galectins would favor the formation of galectin-glycoprotein lattices at the TIL surface and result in a decreased surface motility of the receptors involved in T-cell functions.
Are Galectin Antagonists Candidate Treatments for Clinical Trials?
Remarkably, briefly treating human TILs ex vivo with galectin antagonists is sufficient to strongly increase IFNγ secretion and cytolytic ability, a reactivation that appears unique to galectin antagonists. 4 In contrast, other groups have treated T cells with antibodies specific for inhibitory receptors, such as those aforementioned. This treatment does not provide an immediate functional correction but instead results in an enhanced proliferation of T cells, yielding a higher number of functional T cells a few days later. 6 We have observed that two clinicalgrade galectin antagonists, GCS-100 and GM-CT-01, boost IFNγ secretion upon ex vivo stimulation among ~80% of CD8 + and ~50% of CD4 + patient TIL samples. These TIL samples were obtained from patients bearing tumors of distinct histological origins, including those arising from melanocyte, biliary tract, prostate, esophagus, liver, colon, pancreas, and ovary. Galectin antagonists had no effect on the IFNγ secretory responses of stimulated blood T lymphocytes from donors without cancer. These two compounds have already been injected intravenously in cancer patients without severe side effects.
In addition to its straightforward effect on TIL functions, inhibition of extracellular galectins may have other beneficial antitumoral benefits. Upregulated galectin-3 expression and secretion is a feature of alternative macrophage activation. 7 Galectin antagonists could interrupt the galectin-3 feedback loop that enhances alternative macrophage polarization and activation, dampening chronic inflammation. 7 Moreover, in murine models, extracellular galectin-3 seems to favor breast 8 and melanoma metastases 9 by supporting tumor cell adhesion. Resistance of galectin-3 knock-out mice to melanoma metastasis also correlates with a higher NK cytotoxicity.
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Cautionary Remarks
Considering the pleiotropic roles of galectin-1 and galectin-3 and the fact that the galectin antagonists mentioned above have a broad specificity for several galectins, care must be exercised when using these compounds for human clinical therapy. Indeed, we cannot exclude that galectins cover activated T cells in autoimmune diseases where galectins are abundant and may restrain T-cell functions. Systemic injections of galectin antagonists may thus, in theory, exacerbate some autoimmune diseases. Such systemic injections could also disturb leukocyte migration across vascular and lymphatic endothelium, as it is regulated by galectins.
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